Gavin Marx

6.1k total citations
100 papers, 1.8k citations indexed

About

Gavin Marx is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Gavin Marx has authored 100 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 51 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Gavin Marx's work include Prostate Cancer Treatment and Research (31 papers), Cancer Treatment and Pharmacology (17 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Gavin Marx is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Cancer Treatment and Pharmacology (17 papers) and Radiopharmaceutical Chemistry and Applications (10 papers). Gavin Marx collaborates with scholars based in Australia, United States and United Kingdom. Gavin Marx's co-authors include Howard Gurney, Lisa G. Horvath, Christopher Steer, Martin R. Stockler, Kate Mahon, Paul de Souza, Michael Boyer, Jeremy N. Pulvers, Girish Mallesara and Nick Pavlakis and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Gavin Marx

94 papers receiving 1.8k citations

Peers

Countries citing papers authored by Gavin Marx

Since Specialization

Citations

This map shows the geographic impact of Gavin Marx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Marx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Marx more than expected).

Fields of papers citing papers by Gavin Marx

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Marx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Marx. The network helps show where Gavin Marx may publish in the future.

Co-authorship network of co-authors of Gavin Marx

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Marx. A scholar is included among the top collaborators of Gavin Marx based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Marx. Gavin Marx is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity 2024 ·Journal of the National Comprehensive Cancer Network ·(unknown), Tiffany Li, Hannah C. Timmins, Lisa G. Horvath, Michelle Harrison, Peter Grimison, Gavin Marx, David Goldstein, Susanna B. Park	6
2	A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia 2024 ·Asia-Pacific Journal of Clinical Oncology ·Gavin Marx, Simon Chowdhury, Laurence E. Krieger, Elizabeth Hovey, Jeremy Shapiro, Ben Tran, Thean Hsiang Tan, Siobhan Ng, Henry H. Woo	0
3	Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney, (unknown)	3
4	Has the COVID ‐19 pandemic resulted in more advanced breast cancer? A hospital‐based retrospective study 2024 ·ANZ Journal of Surgery ·(unknown), (unknown), Jordan R. Barrett, (unknown), (unknown), Michael Hughes, Gavin Marx, John Boyages	0
5	Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience 2024 ·Cancer Medicine ·(unknown), (unknown), (unknown), (unknown), Michael Hughes, (unknown), (unknown), (unknown), Senarath Edirimanne, Gavin Marx	1
6	Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer 2024 ·The Prostate ·Kate Mahon, (unknown), Hui‐Ming Lin, Martin R. Stockler, Howard Gurney, Girish Mallesara, Karen Briscoe, Gavin Marx, Celestia S. Higano, Johann S. de Bono, Kim N., Georgina J. Clark, Samuel N. Breit, David A. Brown, Lisa G. Horvath	5
7	Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells 2023 ·Clinical Cancer Research ·Vinod Ganju, Gavin Marx, Scott Pattison, Nancy B. Amaro-Mugridge, Jing Zhao, Bryan R.G. Williams, Jennifer A. MacDiarmid, Himanshu Brahmbhatt	6
8	1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) 2023 ·Annals of Oncology ·Lisa G. Horvath, Ian D. Davis, Andrew Martin, (unknown), Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John A. McCaffrey, Ray McDermott, Nicola Jane Lawrence, Mark Frydenberg, S. Chowdhury, K.N. Chi, Martin R. Stockler, Christopher J. Sweeney	2
9	The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting 2022 ·The Breast Journal ·(unknown), Michael Hughes, Gavin Marx, John Boyages, (unknown), (unknown), (unknown), Senarath Edirimanne, (unknown)	5
10	73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial 2022 ·Annals of Oncology ·Arlene Chan, Manuel Ruíz Borrego, Gavin Marx, Adam Brufsky, (unknown), Michael P. Thirlwell, (unknown), Ron Bose, José Á. García-Sáenz, (unknown), Barbara Pistilli, Johanna Wassermann, (unknown), (unknown), C Singer, (unknown), (unknown), Leanne McCulloch, (unknown)	1
11	A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer 2017 ·International Journal of Cancer ·Hui‐Ming Lin, Kate Mahon, Jacquelyn M. Weir, Piyushkumar A. Mundra, (unknown), Karen Briscoe, Howard Gurney, Girish Mallesara, Gavin Marx, Martin R. Stockler, Robert G. Parton, Andrew J. Hoy, Roger J. Daly, Peter J. Meikle, Lisa G. Horvath	63
12	Correlating Ki67 and other prognostic markers with oncotype DX recurrence score in early breast cancer 2014 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Stephen Clarke, Nick Pavlakis, J Rutovitz, Gavin Marx, Michael Hughes, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
13	THE ADDITION OF ANTI-ANGIOGENIC TYROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS 2013 ·Deakin Research Online (Deakin University) ·(unknown), (unknown), (unknown), (unknown), Mustafa Khasraw, Gavin Marx, Nick Pavlakis	1
14	Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy 2013 ·Supportive Care in Cancer ·(unknown), Elizabeth Hovey, Paul de Souza, Gavin Marx, Phillip Parente, (unknown), Andrew Hill, Antonino Bonaventura, (unknown), Paul Craft, Ehtesham Abdi, Andrew R. Lloyd	27
15	Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab 2011 ·Annals of Oncology ·(unknown), Felicity Murphy, Diana Zannino, Kate Wilson, Michelle M. Cummins, Ehtesham Abdi, A. H. Strickland, R. M. Lowenthal, Gavin Marx, Christos S. Karapetis, Jenny Shannon, David Goldstein, (unknown), Robert Blum, Lorraine A. Chantrill, R. J. Simes, Timothy Price	38
16	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling 2009 ·Cancer Research ·(unknown), Brian Y. Lee, David A. Brown, Mark P. Molloy, Gavin Marx, Nick Pavlakis, Michael Boyer, Martin R. Stockler, Warren Kaplan, Samuel N. Breit, Robert L. Sutherland, Susan M. Henshall, Lisa G. Horvath	86
17	CHEMOTHERAPY IN THE ELDERLY 2008 ·Own your potential (DEAKIN) ·Mustafa Khasraw, Gavin Marx	3
18	Evaluation of the Cockroft–Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients 2004 ·Annals of Oncology ·Gavin Marx, Glen M. Blake, Eleni Galani, Christopher Steer, (unknown), Kathryn Adamson, Dale L. Bailey, Peter Harper	91
19	Non-platinum gemcitabine combinations in non-small cell lung cancer 2002 ·Lung Cancer ·Gavin Marx, Peter Harper	3
20	Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme 2001 ·Journal of Neuro-Oncology ·Gavin Marx, (unknown), (unknown), Frances Boyle, John A. Levi, David Bell, Raymond Cook, Michael T. Biggs, Nicholas Little, Helen Wheeler	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact